Taylor Sheehy

My research focuses on developing next-generation oncology immunotherapeutics. This unique class of drugs aims to modulate the body’s own immune system to recognize and eliminate cancer. With immune checkpoint blockade (ICB) therapy changing the paradigm of cancer treatment, clinicians and scientists are looking for new strategies to improve efficacy and… Read More

About the authors: Co-first author, Kyle Garland earned his Ph.D. in Chemical Engineering in 2021 under the direction of Prof. John Wilson and is currently working for Brooklyn Immunotherapeutics, Inc. in San Diego, California as an R&D scientist investigating in vivo gene editing. His dissertation focused on the… Read More